NCT00307086 · OUTCOME

Overall Survival (OS)

Bortezomib Followed by High-Dose Melphalan and Bortezomib as Conditioning Regimen for Tandem Stem Cell Transplants · Source last updated 2017-03-06

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: MEDIAN
Unit: months
Interval / dispersion: 95% Confidence Interval
Time frame: 40 months post transplant

What was measured

Median overall survival after first peripheral blood stem cell transplant (PBSCT).

Analysis population: All evaluable participants

Groups in this outcome

Autologous PBSCT

bortezomib in combination with high-dose melphalan as a conditioning regimen for autologous peripheral blood stem cell transplant Bortezomib : the maximum tolerated dose (MTD) of bortezomib in combination with high-dose melphalan as a conditioning regimen for autologous stem cell transplant PBSCT : PBSCT #1 Day 0 PBSCT #2 Day 0 (approx 90 days =/- 15 days after PBSCT #1) Melphalan : Day -4 melphalan 100 mg/m2 intravenously over 30 minutes, Day -3 melphalan 100 mg/m2 intravenously over 30 minutes

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Autologous PBSCT	25

Reported measurements

Source class 1

Values in months · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Autologous PBSCT	40	Not reported	32	40	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
lower Limit
32
upper Limit
40
value
40

denoms

counts
group Id
OG000
value
25
units
Participants

description

Median overall survival after first peripheral blood stem cell transplant (PBSCT).

dispersion Type

95% Confidence Interval

groups

description
bortezomib in combination with high-dose melphalan as a conditioning regimen for autologous peripheral blood stem cell transplant Bortezomib : the maximum tolerated dose (MTD) of bortezomib in combination with high-dose melphalan as a conditioning regimen for autologous stem cell transplant PBSCT : PBSCT #1 Day 0 PBSCT #2 Day 0 (approx 90 days =/- 15 days after PBSCT #1) Melphalan : Day -4 melphalan 100 mg/m2 intravenously over 30 minutes, Day -3 melphalan 100 mg/m2 intravenously over 30 minutes
id
OG000
title
Autologous PBSCT

param Type

MEDIAN

population Description

All evaluable participants

reporting Status

POSTED

time Frame

40 months post transplant

title

Overall Survival (OS)

type

PRIMARY

unit Of Measure

months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice